FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:299 January 24, 2002 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

By Susan Quinn. 260 pp. Cambridge, Mass., Perseus Publishing, 2001. $26. ISBN 0-7382-0182-0.

This book is not a mystery story, so I can tell you the ending: 56 percent of patients with multiple sclerosis had a response to placebo in a double-blind, randomized trial, and 56 percent had a response to oral myelin (Myloral). Did the treatment fail, or was it killed by an unusual "placebo effect"? Susan Quinn unfolds the stories of scientists, investors, and patients, all of whom were seeking success. If you are unfamiliar with the literature on multiple sclerosis, the book does read like a mystery that is not solved until the last chapter. The story follows what is . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.